2nd Gene Therapy Immunogenicity

Kongressthemen
The 2nd Gene Therapy Immunogenicity Summit is the industry's definitive forum enabling you to better modulate, measure and predict immune response to your gene therapy candidate.

In the context of ever-increasing gene therapy clinical activity and uncertainty around immunogenicity challenges, the Gene Therapy Immunogenicity Summit will unite large pharma and innovative biotechs to ensure that you're up to speed on the latest approaches to predict, measure

Kongressorganizer (PCO)
Hanson Wade

Anmerkungen
Speakers: Andrew Byrnes, Head Gene Transfer and Immunogenicity Branch, FDA, Klaudia Kuranda, Immunology Lead, Spark Therapeutics, David Markusic, Research Professor, IUPUI, Cathryn Clary, Acting Chief Medical Officer, Bridge Bio and more.

https://go.evvnt.com/754695-1?pid=4832

Frau Ellie Saunders